142 related articles for article (PubMed ID: 17150037)
41. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
42. Src family tyrosine kinases regulate adhesion-dependent tyrosine phosphorylation of 5'-inositol phosphatase SHIP2 during cell attachment and spreading on collagen I.
Prasad N; Topping RS; Decker SJ
J Cell Sci; 2002 Oct; 115(Pt 19):3807-15. PubMed ID: 12235291
[TBL] [Abstract][Full Text] [Related]
43. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner.
Cicha I; Zitzmann R; Goppelt-Struebe M
Int J Biochem Cell Biol; 2014 Jan; 46():39-48. PubMed ID: 24275091
[TBL] [Abstract][Full Text] [Related]
44. SRC inhibitors and angiogenesis.
Schenone S; Manetti F; Botta M
Curr Pharm Des; 2007; 13(21):2118-28. PubMed ID: 17627544
[TBL] [Abstract][Full Text] [Related]
45. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
46. Src inhibitors in lung cancer: current status and future directions.
Rothschild SI; Gautschi O; Haura EB; Johnson FM
Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
[TBL] [Abstract][Full Text] [Related]
47. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
48. The interplay between Src and integrins in normal and tumor biology.
Playford MP; Schaller MD
Oncogene; 2004 Oct; 23(48):7928-46. PubMed ID: 15489911
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
50. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Elsberger B
Crit Rev Oncol Hematol; 2014 Mar; 89(3):343-51. PubMed ID: 24388104
[TBL] [Abstract][Full Text] [Related]
51. Is Src a viable target for treating solid tumours?
Elsberger B; Stewart B; Tatarov O; Edwards J
Curr Cancer Drug Targets; 2010 Nov; 10(7):683-94. PubMed ID: 20578988
[TBL] [Abstract][Full Text] [Related]
52. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
53. Exquisitely specific bisubstrate inhibitors of c-Src kinase.
Brandvold KR; Santos SM; Breen ME; Lachacz EJ; Steffey ME; Soellner MB
ACS Chem Biol; 2015 Jun; 10(6):1387-91. PubMed ID: 25793938
[TBL] [Abstract][Full Text] [Related]
54. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
55. Src kinase and pancreatic cancer.
Hilbig A
Recent Results Cancer Res; 2008; 177():179-85. PubMed ID: 18084959
[TBL] [Abstract][Full Text] [Related]
56. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
57. Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
Lee HJ; Kim E; Jee B; Hahn JH; Han K; Jung KC; Park SH; Lee H
Exp Mol Med; 2002 Jul; 34(3):177-83. PubMed ID: 12216109
[TBL] [Abstract][Full Text] [Related]
58. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
Park SI; Shah AN; Zhang J; Gallick GE
Expert Opin Ther Targets; 2007 Sep; 11(9):1207-17. PubMed ID: 17845146
[TBL] [Abstract][Full Text] [Related]
59. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
[TBL] [Abstract][Full Text] [Related]
60. Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.
Cho NL; Lin CI; Du J; Whang EE; Ito H; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2012 May; 421(3):508-13. PubMed ID: 22521882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
